Literature DB >> 8221615

A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11).

R M Mohammad1, A N Mohamed, M R Smith, N S Jawadi, A al-Katib.   

Abstract

A new human B-cell line, WSU-FSCCL, was established from the peripheral blood of a patient with low-grade follicular small cleaved cell lymphoma in leukemic phase. Both the fresh lymphoma cells and the established cell line exhibit t(14;18)(q32;q21) and t(8;11)(q24;q21) chromosomal translocations, 6q-, 1p+, and +i(1q). PCR analysis confirmed the juxtaposition of the major breakpoint-cluster region of bcl-2 with immunoglobulin heavy chain (JH) gene rearrangements. Southern analysis demonstrated that the 8q24 breakpoint was 5' of c-myc exon 1. The new line grows as a single-cell suspension with a doubling time of approximately 26 hours. It expresses cytoplasmic and cell surface IgM-kappa and reacts with monoclonal antibodies to B-cell antigens. Cells are negative for T-cell and myeloid/monocyte antigens as well as for Epstein-Barr virus nuclear antigen (EBNA). DNA histogram generated by flow cytometry indicated a near diploid stemline. While t(14;18) is common in follicular lymphomas, the t(8;11) is unusual in lymphomas, although it does involve a region frequently aberrant on chromosome 8. The rearrangement of c-myc may have conferred an aggressive clinical behavior seen in the terminal phase of the disease. The role of 11q21 remains undetermined.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8221615     DOI: 10.1016/0165-4608(93)90132-6

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  22 in total

1.  Role of bcl-2 in Epstein-Barr virus-induced malignant conversion of Burkitt's lymphoma cell line Akata.

Authors:  J Komano; K Takada
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata.

Authors:  J Komano; S Maruo; K Kurozumi; T Oda; K Takada
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

3.  Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor.

Authors:  Edi Levi; Liyue Zhang; Amro Aboukameel; Sunny Rishi; Ramzi M Mohammad; Lisa Polin; James S Hatfield; Arun K Rishi
Journal:  Cancer Chemother Pharmacol       Date:  2010-08-31       Impact factor: 3.333

4.  Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo.

Authors:  Yuan Sun; Jack Wu; Amro Aboukameel; Sanjeev Banerjee; Alan A Arnold; Jianyong Chen; Zaneta Nikolovska-Coleska; Yanqiong Lin; Xiaolan Ling; Dajun Yang; Shaomeng Wang; Ayad Al-Katib; Ramzi M Mohammad
Journal:  Cancer Biol Ther       Date:  2008-09-04       Impact factor: 4.742

5.  Lectins from opportunistic bacteria interact with acquired variable-region glycans of surface immunoglobulin in follicular lymphoma.

Authors:  Dunja Schneider; Marcus Dühren-von Minden; Alabbas Alkhatib; Corinna Setz; Cornelis A M van Bergen; Marco Benkißer-Petersen; Isabel Wilhelm; Sarah Villringer; Sergey Krysov; Graham Packham; Katja Zirlik; Winfried Römer; Christian Buske; Freda K Stevenson; Hendrik Veelken; Hassan Jumaa
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

6.  Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study.

Authors:  Erlene K Seymour; Husain Yar Khan; Yiwei Li; Mahmoud Chaker; Irfana Muqbil; Amro Aboukameel; Radhakrishanan Ramchandren; Christiane Houde; Golbon Sterbis; Jay Yang; Divaya Bhutani; Silvana Pregja; Kathy Reichel; Amy Huddlestun; Colleen Neveux; Kelly Corona; Yosef Landesman; Jatin Shah; Michael Kauffman; Sharon Shacham; Ramzi M Mohammad; Asfar S Azmi; Jeffrey A Zonder
Journal:  Clin Cancer Res       Date:  2021-03-30       Impact factor: 12.531

7.  I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma.

Authors:  Ayad Al-Katib; Alan A Arnold; Amro Aboukameel; Angela Sosin; Peter Smith; Anwar N Mohamed; Frances W Beck; Ramzi M Mohammad
Journal:  Mol Cancer       Date:  2010-09-01       Impact factor: 27.401

Review 8.  New targets for the treatment of follicular lymphoma.

Authors:  Nishant Tageja; Subhash Padheye; Prasad Dandawate; Ayad Al-Katib; Ramzi M Mohammad
Journal:  J Hematol Oncol       Date:  2009-12-23       Impact factor: 17.388

9.  An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals.

Authors:  Ramzi M Mohammad; Jack Wu; Asfar S Azmi; Amro Aboukameel; Angela Sosin; Sherwin Wu; Dajun Yang; Shaomeng Wang; Ayad M Al-Katib
Journal:  Mol Cancer       Date:  2009-12-03       Impact factor: 27.401

10.  HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas.

Authors:  Angela M Sosin; Angelika M Burger; Aisha Siddiqi; Judith Abrams; Ramzi M Mohammad; Ayad M Al-Katib
Journal:  J Hematol Oncol       Date:  2012-09-18       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.